Portfolio Comments (0) 17 December 2011

CytoSystems has a simple, effective, quick and low-cost diagnostic tool for bladder cancer

Set up in 2006, Cytosystems Ltd, a Scottish-based company, has developed unique urine-based screening and diagnostic solutions for the detection of cancer of the bladder and prostate comprising:

    • Urine collection protocols
    • Patented cell harvesting device
    • MCM protein antibody
    • Patented staining technology
    • Thin slide preparation
    • Digital cell recognition software

The tests can replace invasive, distressing and expensive endoscopic test procedures. Independent research has confirmed that successfully introducing a nurse-managed diagnostic solution of this type into the clinic could enable earlier, more accurate diagnosis, improve patient care, enhance outcomes and greatly reduce associated healthcare costs by as much as 50%.

The core MCM technology was developed over a twelve-year period by Cancer Research UK at Cambridge University.

More about Cytosystems’ platform technology

Full details for Aurora members only

Register today for free updates of new opportunities
  • Use the Aurora Network to contact growing companies
  • Offer your professional help as executive or director
  • See new investment opportunities in high growth companies
  • We will never pass your details to other lists without your permission
Be part of the economic revival Ask us anything in confidence
Invest £1k, £10k, or £100k
  • Invest in high growth, interesting and well-researched companies
  • Aim for 3x to 10x return from your investment
  • Putting some of your investment funds into high growth businesses can make sense during difficult economic times
  • Choose whether to invest at all and how much with Aurora
  • Join Aurora Private Equity and make your funds grow
Be an angel, be part of it Ask us anything in confidence